NCT07039604Recruiting
Real-World Study of PADN for the Treatment of PAH
Real-World Study of Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Arterial Hypertension (PAH)
Source: ClinicalTrials.gov · Last updated 26 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Real-World Study of PADN for the Treatment of PAH
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 10 Jun 2025
- Start date
- 19 Mar 2025
- Primary completion date
- 30 Dec 2028
- Lead sponsor
- Pulnovo Medical (Wuxi) Co., Ltd.
- NCT number
- NCT07039604
What you commit to
- Study type: Observational
- Planned participants: 200
- From 19 Mar 2025 to the primary completion date, 30 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None specified.
Who the study is looking for
- Diagnosed with PAH and received PADN procedure since March 2024.
- No contraindications to procedure.
- Able to provide informed consent and authorize use of health/research data.
- Compliant with treatment and follow-up requirements.
Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital with Nanjing Medical University Coordinator of this site? Confirm its status | Nanjing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.